vinpocetine has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bickle, M; Chakroun, T; Chiu, WH; Goebel, JN; Höglinger, GU; Höllerhage, M; Koeglsperger, T; Melms, J; Moebius, C; Oertel, WH; Rösler, TW | 1 |
| Adeyemi, OO; Awogbindin, IO; Ishola, IO; Olajiga, AE; Olubodun-Obadun, TG | 1 |
2 other study(ies) available for vinpocetine and alpha-synuclein
| Article | Year |
|---|---|
Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.
Topics: alpha-Synuclein; Animals; Cell Line; Dipyridamole; Drug Discovery; Drug Evaluation, Preclinical; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Mice; Neurons; Neuroprotective Agents; Phosphodiesterase I; Protein Aggregation, Pathological; Vinca Alkaloids | 2017 |
Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and α-synuclein expressions in rats.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Male; Neurodegenerative Diseases; Neuroinflammatory Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone | 2023 |